Lv4
466 积分 2023-11-13 加入
Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity
14天前
已完结
Emergence of ceftazidime-avibactam resistance mediated by KPC variants KPC-71 and KPC-78 in ST463 Pseudomonas aeruginosa
16天前
已关闭
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study
27天前
已完结
Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa
27天前
已完结
Emergence of blaKPC-33-harboring Hypervirulent ST463 Pseudomonas aeruginosa Causing Fatal Infections in China
1个月前
已完结
In vivo acquisition of blaKPC-2 with low biological cost in blaAFM-1-harboring ST463 hypervirulent Pseudomonas aeruginosa from a patient with hematologic malignancy
1个月前
已完结
Clinical characteristics and prognosis of bloodstream infections with carbapenem-resistant Gram-negative organisms in patients with hematological malignancies: a multicenter case-control study in China
1个月前
已完结
Comparison of Ceftolozane-Tazobactam and Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant/Difficult-to-Treat Resistant Pseudomonas aeruginosa Infections: A Systematic Review and Meta-analysis
1个月前
已完结
Current Management Strategies of Difficult-to-Treat Resistant Pseudomonas aeruginosa Infections
1个月前
已关闭
Survival trends in patients with difficult-to-treat, antibiotic-resistant, Gram-negative infections in the era of next-generation antibiotics in the USA: a retrospective cohort study
1个月前
已完结
皖公网安备34019202002308
